2007 signals change for early-stage

Following years of decline in early stage deal activity in the DACH region, statistics for the first three quarters of 2007 reveal that last year could prove to be a turning point of the negative trend. According to unquote's proprietary database Private Equity Insight, 2007 saw an increasing amount of investments in the early stage sector and the highest invested amount since the crash of the Neuer Markt. The market witnessed spectacular life science investment rounds such as the EUR40m funding of immatics biotechnologies co-led by Wellington Partners and 3i, the LSP-led EUR25m financing of Affimed Therapeutics or the EUR20m investment round of Nitec Pharma led by NGN Capital. However the venture revival cannot be attributed to financings in the life science segment alone but mainly to the resurgence of technology venture investments. Here, Web 2.0. in particular was one of the buzz words of the venture scene in 2007 with many VCs backing online networking platforms.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH